SCHEMBL376695

SCHEMBL376695

CC(OCc1ccccc1)C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.53
SLC1A2 P43004 2/20 0.53
SLC1A1 P43005 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 2/20 0.48
ALOX5 P09917 1/20 0.46
PARP10 Q53GL7 1/20 0.45
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.44
EPHX1 P07099 1/20 0.44
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
LTA4H P09960 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18381513 1.00 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL26963671 1.00 SLC1A3 (0.53) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL6354865 0.85 ALDH1A1 (0.51) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL27757196 0.85 KMT2A (0.56) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL138280 0.85 KMT2A (0.56) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL1706675 0.85 KMT2A (0.56) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL138281 0.85 KMT2A (0.56) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL583986 0.84 ALDH1A1 (0.49) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL2821271 0.84 ALDH1A1 (0.49) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL583985 0.84 ALDH1A1 (0.49) SLC1A3SLC1A2SLC1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247794-A1 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) 2020-08-06 US claimed
EP-3365819-A2 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 Mangosuthu University Of Technology (ZA) 2018-08-29 EP claimed
WO-2017070719-A2 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) 2017-04-27 WO claimed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO claimed
CN-119365502-A Polymer emulsion, and one-part thermosetting resin composition, two-part thermosetting resin composition, paint, resin cured film, and coating film using the same 株式会社力森诺科 2025-01-24 CN disclosed
US-20240228501-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
EP-4293023-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2023-12-20 EP disclosed
CN-117177974-A Imidazole-containing condensed ring derivative, preparation method and medical application thereof 长春金赛药业有限责任公司 2023-12-05 CN disclosed
EP-3365330-B1 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 MANGOSUTHU UNIV OF TECHNOLOGY (ZA) 2023-06-07 EP disclosed
EP-3365819-B1 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 MANGOSUTHU UNIV OF TECHNOLOGY (ZA) 2023-06-07 EP disclosed
US-11548860-B2 Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) 2023-01-10 US disclosed
CN-108701171-B Pharmacophores, compounds and methods having application in the treatment of cancer by inhibition of CYP17a1 and CYP19a1 马古苏托科技大学 2022-06-10 CN disclosed
US-20030004166-A1 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors PFIZER INC. 2003-01-02 US disclosed
EP-1247809-A2 Triazine compounds useful as sorbitol dehydrogenase inhibitors Pfizer Products Inc. (US) 2002-10-09 EP disclosed
EP-0961766-A1 PHENOXYACETIC ACID DERIVATIVES AND THEIR USE AS HERBICIDES Rhone Poulenc Agro (FR) 1999-12-08 EP disclosed
WO-1998034898-A1 PHENOXYACETIC ACID DERIVATIVES AND THEIR USE AS HERBICIDES RHONE-POULENC AGRO (FR) 1998-08-13 WO disclosed
EP-0821667-A1 NEW HYDROXIMIC ACID DERIVATIVES RHONE-POULENC AGROCHIMIE (FR) 1998-02-04 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed
WO-1996033164-A1 NEW HYDROXIMIC ACID DERIVATIVES RHONE-POULENC AGROCHIMIE (FR) 1996-10-24 WO disclosed
EP-0731797-A1 PARAMAGNETIC CHELATES FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSIS BRACCO S.p.A. (IT) 1996-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247794-A1 PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 CYP19A1, CYP26A1, CYP21A2 SLC1A3 1603/4885SLC1A2 1545/4885SLC1A1 805/4885
US-20030004166-A1 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors SLC5A1, SLC5A2, ADH5 SLC1A3 124/4885SLC1A2 73/4885SLC1A1 70/4885
US-11548860-B2 Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 CYP19A1, CYP26A1, CYP21A2 SLC1A3 2027/4885SLC1A2 1686/4885SLC1A1 963/4885
US-20240228501-A1 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE KISS1R, CYP3A43, SLC6A11 SLC1A3 102/4885SLC1A2 506/4885SLC1A1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.